You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Litigation Details for Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

✉ Email this page to a colleague

« Back to Dashboard

Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

Docket	⤷ Try a Trial	Date Filed	2017-05-31
Court	District Court, D. Massachusetts	Date Terminated	2018-07-31
Cause	35:271 Patent Infringement	Assigned To	Mark Lawrence Wolf
Jury Demand	Both	Referred To
Patents	8,183,007; 8,367,649; RE38,551
Link to Docket	External link to docket

Small Molecule Drugs cited in Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd.

The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .

Biologic Drugs cited in Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd.

The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .

Details for Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-11	16	Exhibit 22	9,046 8,494 8,183 7,665 7,548 6,844 6,986 …Company. Patents The Company's subsidiaries have made a practice of obtaining patent protection…two sets of patents related specifically to REMICADE ® (infliximab). The first set of patents is co-owned… license to NYU's interests in the patents. These patents have expired in all countries outside the…States, the latest of these patents expires in September 2018 and this patent stands rejected and is subject	External link to document
2018-06-01	316	Exhibit A	UCB”) own and/or license U.S. Patent No. RE38,551. The ’551 patent covers lacosamide, an anti-epileptic…551 patent. Appellants rely on the ’301 patent only for their argument that the ’551 patent is …obviousness-type double patenting. Like its parent ’729 patent, the ’301 patent claims compounds of …’301 patent and the asserted claims of the ’551 patent rendered the claims patentably distinct…a second patent not patentably distinct from the claims of the first patent.” Otsuka Pharm	External link to document
2017-08-21	33	Exhibit 6	Antitrust 8,367,649 Product liability…2017 31 July 2018 1:17-cv-11008 830 Patent Both District Court, D. Massachusetts	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.